Key Takeaways
- In the early AIDS epidemic, treatment was limited to basic care; millions died and families were torn apart.
- U.S. leadership through PEPFAR (since 2003) has saved >26 million lives, prevented ~8 million pediatric infections, and boosted U.S.–Africa trade.
- Recent breakthroughs include long‑acting HIV PrEP (injection every six months) and a pipeline of cheaper, better prevention and treatment options.
- Despite these tools, 2024 saw 630,000 HIV‑related deaths and 1.3 million new infections—a failure of delivery, not of science.
- Congress and the President have funded a strategic shift to country‑led HIV programs and continued Global Fund support, but billions remain unspent in Washington.
- Effective transition requires clear benchmarks, robust data, and sustained backing for lower‑income nations, especially those in economic distress.
- An innovation fund can scale private‑sector ideas (e.g., Zipline drones, AI, telehealth) to reach tens of millions more people.
- Community health workers—many of whom have been terminated—are essential for getting shots in arms and combating stigma.
- Public opinion strongly supports maintaining PEPFAR funding (≈80 % of voters), underscoring a bipartisan mandate to finish the fight against AIDS.
The early years of the AIDS crisis were marked by helplessness; clinicians could offer only aspirin, blankets, love, and prayers as the virus swept through communities, shattering families and leaving millions of orphans worldwide. That stark reality forged a resolve to turn the tide, a resolve that has since been bolstered by American leadership and unprecedented global cooperation.
Today, the landscape is markedly different. Scientific progress has yielded long‑acting HIV pre‑exposure prophylaxis (PrEP) that requires just a single injection every six months, effectively stopping the virus in its tracks. A pipeline of even more affordable and effective prevention and treatment options is advancing, offering hope that the tools to end AIDS are finally within reach.
Yet, the gap between available tools and actual outcomes remains troublingly wide. In 2024 alone, 630,000 people died from HIV‑related causes and 1.3 million acquired the virus—numbers that reflect not a lack of science but a failure of delivery. The bipartisan President’s Emergency Plan for AIDS Relief (PEPFAR), launched in 2003, has been a cornerstone of the response, saving more than 26 million lives, averting roughly eight million new infections in children, reducing health‑care and economic burdens in the world’s poorest nations, and correlating with a fourfold increase in U.S. exports to Africa.
Recognizing both the achievements and the work still ahead, the 2025 and 2026 federal budgets earmarked resources for a strategic transition of PEPFAR toward country‑led and country‑run HIV programs. The aim is to preserve decades of progress while empowering partner nations to own their responses, leveraging continued support from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Unfortunately, a substantial portion of the allocated billions remains idle in Washington rather than reaching the clinics and communities that need them most. This includes funds earmarked for newly negotiated U.S.–country compacts and for the Global Fund, both essential to a smooth transition.
The administration’s “America First Global Health Strategy” frames these compacts as a sensible evolution, but their success hinges on being well‑designed, adequately funded, and closely monitored—particularly for African countries facing economic distress. Establishing clear benchmarks and metrics, backed by rigorous data collection, will enable course corrections and ensure accountability.
Innovation also features prominently in the budget. An innovation fund is intended to scale bold ideas from the American private sector, such as the drone delivery network Zipline, which has already proved its worth in hard‑to‑reach regions. Further investment in drones, artificial intelligence, and telehealth platforms could extend lifesaving supplies to tens of millions more people, faster and more efficiently than ever before.
Equally vital is the human element: community health workers remain the frontline agents who “get shots in arms,” conduct outreach, combat stigma, and support retention in care. Too many of these workers have been terminated, undermining efforts to reach vulnerable populations. Re‑engaging and expanding this workforce is essential for any scaling initiative.
The moral and economic imperative to act is stark. The cost‑benefit analysis of ending AIDS is unmistakably favorable; inaction risks a global resurgence, potentially driven by drug‑resistant HIV that no nation—including the United States—could afford to contain. Public opinion underscores the urgency: a recent poll by the President’s own pollster shows that roughly 80 % of voters agree the United States must maintain its PEPFAR funding commitment to sustain access to preventive and life‑saving treatments.
In sum, we possess cutting‑edge medicines, available financing, proven policies, and capable partners. The missing link is the urgent, coordinated deployment of these resources—scaling procurement and distribution, sustaining faith‑ and community‑based outreach, and harnessing innovative delivery models. If the administration acts swiftly to release the stalled funds and translates policy into on‑the‑ground action, the world can finally seize the moment and end AIDS once and for all.